Menu
Search
|

Menu

Close
X

Argos Therapeutics Inc ARGS.OQ (NASDAQ Stock Exchange Capital Market)

1.45 USD
+0.01 (+0.69%)
As of Feb 16
chart
Previous Close 1.44
Open 1.45
Volume 34,895
3m Avg Volume 101,710
Today’s High 1.49
Today’s Low 1.41
52 Week High 98.00
52 Week Low 1.39
Shares Outstanding (mil) 54.97
Market Capitalization (mil) 9.79
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
1
FY15
1
EPS (USD)
FY17
-17.868
FY16
-37.427
FY15
-73.107
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
20.16
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
-200.62
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Hubert Birner
Independent Chairman of the Board, Since 2005
Salary: --
Bonus: --
Jeffrey Abbey
President, Chief Executive Officer, Director, Since 2010
Salary: $379,788.00
Bonus: $163,800.00
Richard Katz
Chief Financial Officer, Vice President, Since 2016
Salary: --
Bonus: --
Lori Harrelson
Vice President - Finance, Since 2011
Salary: $120,972.00
Bonus: $7,000.00
John Menditto
Vice President - Corporate Communications & Investor Relations, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

4233 TECHNOLOGY DR
DURHAM   NC   27704-2173

Phone: +1919.2876300

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

SPONSORED STORIES